Search

Levocabastine

Levocabastine is a selective second-generation H1-receptor antagonist used for allergic conjunctivitis. Levocabastine was discovered at Janssen Pharmaceutica in 1979.

Elagolix

unmet needs of women who are affected by endometriosis, depending on their specific type and severity of endometriosis pain. … In particular, estimates suggest that one in ten women of reproductive age is affected by endometriosis and experience debilitating pain symptoms [A35868, A35869, F801].

Gadobenic acid

[A1139] Gadobenate dimeglumine was approved by the FDA in November 2004 under the brand name MultiHance.[A263166] … [A263166] As gadobenate dimeglumine is specifically taken up by hepatocytes and excreted through the biliary system, it is a useful contrast agent for liver MRI.

Methacholine

[A229648, L31763] Methacholine was granted FDA approval on October 31, 1986, and is marketed under the trademark PROVOCHOLINE® by Methapharm Inc.[L31763] … [A229598, A229603] Although the underlying pathology of AHR is complex, ASM contraction can be stimulated by cholinergic agonists that activate M₃ muscarinic receptors that stimulate ASM contraction

Mephenytoin

These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subunit alpha.

Phenindione

Phenindione has actions similar to warfarin, but it is now rarely employed because of its higher incidence of severe adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p234)

Nelarabine

[A258719] Nelarabine was first granted accelerated approval by the FDA on October 28, 2005, and was manufactured under the trademark name ARRANON by GlaxoSmithKline. … [A15220] Subsequently, nelarabine was also approved by both Health Canada and European Medicines Agency in 2007 under the trademark name ATRIANCE.[L45874,L45879]

Neisseria meningitidis group Y capsular polysaccharide tetanus toxoid conjugate antigen

Abciximab

Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules

Melphalan

[L40928] It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.